TY - JOUR
T1 - The clinical features and treatment modality of esophageal neuroendocrine tumors
T2 - A multicenter study in Korea
AU - Neuroendocrine tumor study group
AU - Lee, Chang G.
AU - Lim, Yun J.
AU - Park, Seun J.
AU - Jang, Byung I.
AU - Choi, Seok R.
AU - Kim, Jae K.
AU - Kim, Yong Tae
AU - Cho, Joo Y.
AU - Yang, Chang H.
AU - Chun, Hoon J.
AU - Song, Si Y.
N1 - Funding Information:
No grant funding was received for this study. We deeply appreciate the participation of the data collection regarding gastroenteropancreatic NETs in 25 hospitals.
Publisher Copyright:
© 2014 Lee et al.
PY - 2014/8/7
Y1 - 2014/8/7
N2 - Background: Neuroendocrine tumors (NETs) of the esophagus are extremely rare, and few cases have been reported worldwide. Thus, a comprehensive nationwide study is needed to understand the characteristics of and treatment strategy for esophageal NETs. Methods: We collected data on esophageal NET patients from 25 hospitals in Korea from 2002-2012. The incidence, location, clinical symptoms, histopathology, treatment response, and the biochemical, radiologic and endoscopic characteristics of esophageal NETs were surveyed. Results: Among 2,037 NETs arising in different gastrointestinal sites, esophageal NETs were found in 26 cases (1.3%). The mean patient age was 60.12 ± 9.30 years with a 4:1 male predominance. In endoscopic findings, 76.9% (20/26) of NETs were located in the lower third of the esophagus and the mean size was 2.34 ± 1.63 cm. At diagnosis, more than half the patients (15/26, 57.7%) had regional lymph node metastasis or widespread metastasis. Endoscopic resection was conducted in three cases, and in all three of them, lymph node metastasis was not found and tumor size was below 1.0 cm. All tumors were completely removable through endoscopic procedures and there was no recurrence during the follow-up period. Eighteen other patients received an operation, chemotherapy or both. Among them, nine patients (50.0%) expired because of the progression of their cancer or post-operative complications. In Kaplan-Meier survival analysis, only tumor size (more than 2.0 cm) showed prognostic significance (P = 0.045). Conclusions: Despite the general assumption that gastrointestinal NETs are benign and slow-growing tumors, the prognosis of advanced esophageal NETs is not favorable.
AB - Background: Neuroendocrine tumors (NETs) of the esophagus are extremely rare, and few cases have been reported worldwide. Thus, a comprehensive nationwide study is needed to understand the characteristics of and treatment strategy for esophageal NETs. Methods: We collected data on esophageal NET patients from 25 hospitals in Korea from 2002-2012. The incidence, location, clinical symptoms, histopathology, treatment response, and the biochemical, radiologic and endoscopic characteristics of esophageal NETs were surveyed. Results: Among 2,037 NETs arising in different gastrointestinal sites, esophageal NETs were found in 26 cases (1.3%). The mean patient age was 60.12 ± 9.30 years with a 4:1 male predominance. In endoscopic findings, 76.9% (20/26) of NETs were located in the lower third of the esophagus and the mean size was 2.34 ± 1.63 cm. At diagnosis, more than half the patients (15/26, 57.7%) had regional lymph node metastasis or widespread metastasis. Endoscopic resection was conducted in three cases, and in all three of them, lymph node metastasis was not found and tumor size was below 1.0 cm. All tumors were completely removable through endoscopic procedures and there was no recurrence during the follow-up period. Eighteen other patients received an operation, chemotherapy or both. Among them, nine patients (50.0%) expired because of the progression of their cancer or post-operative complications. In Kaplan-Meier survival analysis, only tumor size (more than 2.0 cm) showed prognostic significance (P = 0.045). Conclusions: Despite the general assumption that gastrointestinal NETs are benign and slow-growing tumors, the prognosis of advanced esophageal NETs is not favorable.
KW - Esophagus
KW - Neuroendocrine tumor
KW - Prognosis
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=84905963589&partnerID=8YFLogxK
U2 - 10.1186/1471-2407-14-569
DO - 10.1186/1471-2407-14-569
M3 - Article
C2 - 25098730
AN - SCOPUS:84905963589
SN - 1471-2407
VL - 14
JO - BMC Cancer
JF - BMC Cancer
IS - 1
M1 - 569
ER -